The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.

Authors

Aaron J Siegler
Farah Mouhanna, George Washington University
Robertino Mera Giler
Kevin Weiss
Elizabeth Pembleton
Jodie Guest
Jeb Jones
Amanda Castel, George Washington University
Howa Yeung
Michael Kramer
Scott McCallister
Patrick S Sullivan

Document Type

Journal Article

Publication Date

12-1-2018

Journal

Annals of Epidemiology

Volume

28

Issue

12

Inclusive Pages

841-849

DOI

10.1016/j.annepidem.2018.06.005

Keywords

Adolescent; Adult; Age Distribution; Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pre-Exposure Prophylaxis; Prescriptions; Prevalence; United States; Young Adult

Comments

Epub 2018 Jun 15

APA Citation

Siegler, A., Mouhanna, F., Giler, R., Weiss, K., Pembleton, E., Guest, J., Jones, J., Castel, A., Yeung, H., Kramer, M., McCallister, S., & Sullivan, P. (2018). The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.. Annals of Epidemiology, 28 (12). http://dx.doi.org/10.1016/j.annepidem.2018.06.005

Peer Reviewed

1